RET and non-small cell lung carcinoma: A phase 2 trial enrolling patients with NSCLC and recurrent gene fusions first demonstrated evidence of clinical benefit with cabozantinib in three patients with RET fusions, with partial responses in two patients and prolonged disease stability in one patient [32,116].